Zacks Investment Research cut shares of Teligent (NASDAQ:TLGT) from a hold rating to a sell rating in a research report sent to investors on Tuesday, Zacks.com reports.

According to Zacks, “Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. “

Separately, ValuEngine upgraded shares of Teligent from a hold rating to a buy rating in a research report on Wednesday, September 4th.

Shares of NASDAQ TLGT opened at $0.96 on Tuesday. The firm has a 50 day moving average of $0.81 and a 200 day moving average of $0.86. The company has a current ratio of 1.61, a quick ratio of 0.86 and a debt-to-equity ratio of 23.23. The firm has a market capitalization of $51.70 million, a price-to-earnings ratio of -2.91 and a beta of 1.29. Teligent has a 12-month low of $0.42 and a 12-month high of $4.00.

Teligent (NASDAQ:TLGT) last announced its earnings results on Monday, August 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The business had revenue of $18.34 million for the quarter, compared to the consensus estimate of $17.58 million. Teligent had a negative net margin of 46.67% and a negative return on equity of 102.17%. Sell-side analysts predict that Teligent will post -0.18 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its position in Teligent by 496.8% during the second quarter. JPMorgan Chase & Co. now owns 59,887 shares of the company’s stock valued at $37,000 after buying an additional 49,852 shares during the period. TENOR CAPITAL MANAGEMENT Co. L.P. bought a new stake in Teligent during the second quarter valued at approximately $44,000. Morgan Stanley grew its position in Teligent by 247.0% during the second quarter. Morgan Stanley now owns 72,655 shares of the company’s stock valued at $45,000 after buying an additional 51,718 shares during the period. Jane Street Group LLC bought a new stake in Teligent during the second quarter valued at approximately $46,000. Finally, SG Americas Securities LLC bought a new stake in Teligent during the second quarter valued at approximately $47,000. Institutional investors own 55.31% of the company’s stock.

Teligent Company Profile

Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.

Featured Story: CBOE Russell 2000® Volatility Index

Get a free copy of the Zacks research report on Teligent (TLGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.